Introduction
Methods
Patient Enrollment
FAPI Imaging
Image Interpretation
Statistical Methods
Results
Baseline Characteristics
Visual and Quantitative Assessment of Myocardial FAPI Uptake in the Overall Cohort
Association of Myocardial FAPI Uptake with Patient Characteristics and Clinical Parameters
Overall N = 32 | Visual uptake N = 6 | No visual uptake N = 26 | P value | |
---|---|---|---|---|
Male sex, N | 15 (46.9%) | 5 (83.3%) | 10 (38.5%) | .08 |
Age at FAPI scan, years | 58.7 ± 14.9 | 70.8 ± 10.1 | 56.0 ± 14.6 | .03 |
History of CAD, N | 3 (9.4%) | 3 (50%) | 0 | < .01 |
History of MI, N | 2 (3.1%) | 2 (33.3%) | 0 | .03 |
LVEF, % | 57.5 ± 7.3 | 46.0±8.5 | 60.1 ± 4.2 | < .01 |
Nicotine abuse, N | 7 (21.9%) | 1 (16.7%) | 6 (23.1%) | 1.0 |
Arterial hypertension, N | 17 (53.1%) | 5 (83.3%) | 12 (46.2%) | .18 |
Diabetes, N | 6 (18.8%) | 2 (33.3%) | 4 (15.4%) | .31 |
Atrial fibrillation, N | 2 (3.1%) | 0 | 2 (7.7%) | 1.0 |
CKD, N | 4 (12.5%) | 2 (33.3%) | 2 (7.7%) | .15 |
Cancer entity, N | ||||
Pancreatic | 18 (56.3%) | 2 (33.3%) | 16 (61.5%) | .03 |
Melanoma | 2 (6.3%) | 1 (16.7%) | 1 (3.8%) | .47 |
Osteosarcoma | 2 (6.3%) | 0 | 2 (7.7%) | .37 |
Cervix | 1 (3.1%) | 0 | 1 (3.8%) | .53 |
Colorectal | 1 (3.1%) | 0 | 1 (3.8%) | .53 |
Hypopharynx | 1 (3.1%) | 0 | 1 (3.8%) | .53 |
Larynx | 1 (3.1%) | 1 (16.7%) | 0 | .10 |
Lung | 1 (3.1%) | 0 | 1 (3.8%) | .53 |
Nerve sheath tumor | 1 (3.1%) | 0 | 1 (3.8%) | .53 |
Ovarian | 1 (3.1%) | 0 | 1 (3.8%) | .53 |
Thyroid gland | 1 (3.1%) | 1 (16.7%) | 0 | .10 |
Tongue | 1 (3.1%) | 0 | 1 (3.8%) | .10 |
Urinary bladder | 1 (3.1%) | 1 (16.7%) | 0 | .53 |
Previous chemotherapy | ||||
Antibodies | 5 (15.6%) | 1 (16.7%) | 4 (15.4%) | .68 |
Anthracyclines | 3 (9.4%) | 0 | 3 (11.5%) | .26 |
Antimetabolites | 18 (56.3%) | 2 (33.3%) | 16 (61.5%) | .03 |
Platine derivates | 20 (62.5%) | 2 (33.3%) | 18 (69.2%) | .01 |
Topoisomerase inhibitors | 12 (37.5%) | 1 (16.7%) | 11 (42.3%) | .07 |
Alkylating agents | 3 (9.4%) | 0 | 3 (11.5%) | .26 |
Taxane agents | 10 (31.3%) | 2 (33.3%) | 8 (30.8%) | .52 |
Patient ID | Tracer uptake | CAD | MI | Location of MI; treated coronary vessel | Time between infarction/intervention and imaging |
---|---|---|---|---|---|
2 | Posterior wall (main uptake) Antero-septal | Yes | No | PTCA/DES RCA 2012 | |
7 | Antero-septal | Yes | Yes | PTCA/DES proximal LAD for MI 09/2019 | MI LAD: 5 days |
10 | LV circumferential | Yes | Yes | PTCA/DES for MI LAD/RCX 2012 and elective PTCA/DES RCA 2018 | MI LAD/RCX: 2713 days |
22 | Lateral | No | No | – | |
29 | Apical | No | No | – | |
31 | LV | No | No | – |
R2 | P value | |
---|---|---|
CAD | .16 | .03 |
Age | .15 | .04 |
LVEF | .74 | < .01 |
Sex | .01 | .65 |
MI | .14 | .04 |
Nicotine | .19 | .17 |
Hypertension | .04 | .29 |
Diabetes | .01 | .68 |
CKD | .01 | .97 |
AF | .10 | .08 |